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Abstract: It is now undeniable that laboratory testing is 
vital for the diagnosis, prognostication and therapeutic 
monitoring of human disease. Despite the many advances 
made for achieving a high degree of quality and safety in 
the analytical part of diagnostic testing, many hurdles in 
the total testing process remain, especially in the preana-
lytical phase ranging from test ordering to obtaining and 
managing the biological specimens. The Working Group 
for the Preanalytical Phase (WG-PRE) of the European 
Federation of Clinical Chemistry and Laboratory Medicine 
(EFLM) has planned many activities aimed at mitigating 
the vulnerability of the preanalytical phase, including 
the organization of three European meetings in the past 
7 years. Hence, this collective article follows the previous 
three opinion papers that were published by the EFLM WG-
PRE on the same topic, and brings together the summaries 
of the presentations that will be given at the 4th EFLM-BD 
meeting “Improving quality in the preanalytical phase 
through innovation” in Amsterdam, 24–25 March, 2017.
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Introduction
In the era of personalized (precision) medicine, laboratory 
diagnostics is becoming as vital as ever for diagnosing, 
assessing therapeutic response and monitoring human 
pathologies [1, 2]. The assurance of quality throughout the 
total testing process has always represented a crucial issue 
in laboratory medicine. Despite the advances that have 
unquestionably allowed to achieve a much greater degree 
of quality and safety in diagnostic testing, many hurdles 
still remain to be overcome, especially in all those activi-
ties ranging from test ordering to obtaining and manag-
ing the biological specimens [3–5]. In keeping with these 
issues, the European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM) has established a specific 
Working Group for the Preanalytical Phase (WG-PRE), the 
aims of which are mainly aimed at mitigating the vulner-
ability of many preanalytical activities, releasing official 
documents, guidelines and recommendations, as well as 
providing continuous education for laboratory profession-
als and other healthcare operators. The WG has already 
published many documents on the harmonization and/or 
standardization of preanalytical activities [6–13], and has 
also been proactive in organizing many educational meet-
ings across Europe. This collective article hence follows 
the previous three opinion papers that were published by 
the EFLM WG-PRE on the same topic, in concert with the 
first [14], second [15] and third [16] join EFLM-BD meetings 
which were held in Parma, Zagreb and Porto. This article 
also anticipates and summarizes the concepts expressed 
in the various lectures of the fourth EFLM-BD meeting 
“Improving quality in the preanalytical phase through 
innovation”,  Amsterdam, 24–25 March, 2017.
How is the EFLM WG-PRE improving  
the quality of the preanalytical 
phase in Europe
The EFLM WG-PRE has intensively worked for the last 
4  years with a number of key issues. The primary issue 
has been to disseminate knowledge about the impor-
tance of preanalytical factors to relevant persons within 
the laboratory milieu all across Europe. This has been 
achieved through the three previous EFLM-BD European 
Conferences on the Preanalytical Phase and by publica-
tion of opinion papers and a number of study results – an 
effort that hopefully will continue. The second issue has 
been to identify key areas, where either knowledge was 
missing or where the existing knowledge needed clarifica-
tion. This led to a more focused effort within a number of 
topics, namely fasting, patient and sample identification, 
tube validation, order of draw and venous blood sam-
pling. Clarification studies, recommendations or opinion 
papers have been published about all these topics, with 
the primary goal to cover the preanalytical area with 
EFLM guidelines, enabling national societies as well as 
local laboratory entrepreneurs to improve the conditions 
within the preanalytical area.
What is the hospital point of view 
about laboratory innovations
Many ongoing policies contemplating substantial changes 
in healthcare systems have a deep impact on the organiza-
tion and structure of laboratories, as well as on and the 
relationship between laboratory professionals, physicians 
and patients.
There is a mounting debate between healthcare 
administrators, who increasingly consider clinical labora-
tory as a commodity, and laboratory professionals, who 
instead forcefully defend the role of laboratory as a facil-
ity providing high value in terms of the ratio between cost 
and outcomes [17]. Although the vast majority of general 
costs of the total testing process is attributable to extra-
analytical issues, the various aspects of preanalytical 
phase, as well as their actual impact on quality and inter-
pretation of test results is usually underestimated in this 
debate. Centralization of laboratories is universally driven 
by healthcare organizations to cut down costs [18]. Labo-
ratory activity is characterized by high throughput and 
short turnaround time (TAT), but the transportation of 
biological materials remains a real but mostly neglected 
issue [19]. Hence, the transportation modalities should 
be clearly specified and standardized, also pertaining to 
those tests usually performed in specialized laboratories 
(e.g. metabolomics, micro RNAs, liquid biopsy), as well 
as prenatal screening of congenital diseases (e.g. cell-free 
fetal DNA).
Soon the European Union (EU) is expected to release 
a new set of regulations for medical devices, which will 
then be implemented for the next 2  years. Hence, the 
role of laboratories in evaluating medical devices will 
be strongly emphasized, also entailing the generation 
of documents supporting the quality of devices and 
proposing supplies of different devices. This practice 
is essential at a local level, but the role of preanalytical 
phase experts will also be important for defining and 
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evaluating the general characteristics of devices and/or 
procedures [10]. Notably, the use of health technology 
assessment (HTA) for evaluating new technologies and 
devices is universally appreciated by national/regional 
healthcare systems, but will increasingly be used in the 
field of in vitro diagnostic testing [20]. A machine learn-
ing approach using computer-assisted programs may also 
emerge as a breakthrough for evaluating and interpret-
ing laboratory data, especially for validating reference 
ranges in association with many other individual and 
demographical characteristics.
Innovations: from the point of view 
of the medical company
Innovation by medical companies is more than just good 
product design. It starts by understanding end user 
needs and expectations, through design, development 
and manufacturing phases, with innovation in how the 
product is justified to hospital management and in its suc-
cessful implementation. The research and development 
strategies such as global product development process 
(GPDS), design for six sigma (DFSS) and six sigma manu-
facturing are crucial to this success [21]. In order to under-
stand needs, interviews are conducted, questionnaires 
implemented, processes observed and partnering with 
key stakeholders completed throughout the design and 
implementation process. With the design of a new separa-
tor technology Becton Dickinson (BD) (Becton Dickinson, 
Franklin Lakes, NJ, USA), interviewed hundreds of end 
users and a clear message was the need for both quality 
and efficiency benefits. Initial prototypes were tested in 
‘real life’ hospital environments, to understand how the 
design worked which influenced the final design.
Understanding patient needs and product usage has 
led to new designs that are both more comfortable for the 
patient and easier to use, resulting in improved patient 
satisfaction, safety for the end user and sample quality 
(e.g. ultra-thin wall needle technology, enabling smaller 
gauges to be used, improving patient comfort without 
impacting the sample quality) [22, 23].
The end user has to be able to justify the product to 
their management, through demonstrating the functional 
performance and the financial benefits of the products. In 
the case of the BD Barricor, through its eValidate program 
Becton Dickinson can provide a customized validation 
formulary. Functional and financial benefits are demon-
strated through performance studies and budget impact 
models. These are all part of expected service innovations 
that go hand in hand with product innovation. This deliv-
ery of both product and service innovation enables the 
successful implementation of new products that benefit 
the laboratory, the patient, the nursing staff and the hos-
pital management.
Preanalytical resource center  
at Haukeland University Hospital
To deal with challenges within the preanalytical field, the 
Laboratory of Clinical Biochemistry at Haukeland Uni-
versity Hospital has established a preanalytical resource 
center, including also other laboratories in the laboratory 
clinic such as sections for microbiology, endocrinology, 
pathology, medical genetics and molecular medicine, 
immunology and transfusion medicine. The center con-
sists of biomedical laboratory scientists, scientists with 
PhD degrees and a professor, all with several years of 
experience within laboratory practice and preanalyti-
cal research. The professional development, research, 
instruction and education within the preanalytical field 
are the main focus of the center, aimed at gathering exper-
tise, making visible and improving the competence within 
the preanalytical field; stimulating preanalytical research; 
supervising Master’s and PhD students within preanalyti-
cal research; offering guidance to public health workers 
and researchers; and presenting news and information at 
the preanalytical resource center web page.
“Blodprøvetaking i praksis” (Phlebotomy in prac-
tice) [24], which was written and published by biomedi-
cal laboratory scientists working in the local laboratory. 
One scientist graduated for the PhD grade “Estimation 
of Preanalytical Uncertainty in Clinical Chemistry” [25]. 
Evidence-based procedures for venous and capillary 
phlebotomy, and accurate patient identification have 
been published at Helsebiblioteket (Health library) [26]. 
 Preanalytical sample handling instructions for biochemi-
cal components are given in the database “analyseover-
sikten.no”.
The center is arranging internal lessons, gives lec-
tures and participates at conferences aimed at increasing 
the knowledge about preanalytical variables. We are also 
supervising Master’s degree students within preanalytical 
research. We are also involved in the recently established 
Biobank Haukeland. Research is an ongoing enterprise for 
estimating preanalytical uncertainty, patient safety and 
identification.
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Innovations within the laboratory
Many laboratories are currently considering the instal-
lation of total laboratory automation (TLA) systems for 
routine clinical chemistry and laboratory hematology. 
Advantages of TLA include cost reduction and improved 
TAT. Since 2010 a TLA system was installed at University 
Hospitals Leuven (Belgium) for routine chemistry, immu-
nochemistry, infectious serology, hematology, coagula-
tion and hemoglobin A1c (HbA1c). The track offers the 
possibility for bulk input, volume detection, aliquoter 
and storage. To further improve the preanalytical work-
flow, TLA was combined with a number of additional 
measures including electronic order entry on the wards, 
use of plasma instead of serum and partial automation of 
our workflow for therapeutic drug monitoring and 25-OH- 
vitamin D.
Liquid chromatography tandem mass spectrometry 
(LC-MSMS), which has been used in specialized labora-
tories for decades, has become increasingly popular in 
clinical laboratories in recent years. This is mainly due 
to the high sensitivity and specificity of this technology. 
The main applications in routine clinical practice include 
therapeutic drug monitoring, clinical toxicology and hor-
monology. Nevertheless, integration in a routine work-
flow, and hence application in routine laboratories, is still 
hampered by laborious and difficult-to-automate sample 
pretreatment protocols. This is particularly true for whole 
blood analysis. The LC-MSMS analyses are therefore often 
performed by dedicated laboratory technicians and their 
incorporation into routine workflow remains a challenge.
Recently, the preanalytical sample pretreatment has 
been partially automated in the laboratory of University 
Hospitals Leuven, also incorporating LC-MSMS analysis 
for tacrolimus, cyclosporin, everolimus and sirolimus 
and 25-OH-vitamin D into the routine workflow. These 
LC-MSMS analyses can be performed by the same labora-
tory technicians in charge of the routine clinical chemistry 
platform.
How using technology can improve 
phlebotomy and create better 
sample quality
The North Bristol NHS Trust’s aim is to provide “excep-
tional healthcare personally delivered”, which the trust 
monitors through patient satisfaction surveys. As part 
of this ethos to meet the needs of patients, and strive to 
provide exceptional healthcare, the combined Blood 
Sciences has been innovative in how it manages and 
improves the quality of phlebotomy services it provides 
to the Trust. Key to improving the quality of the service is 
monitoring and continuous improvement of the phlebot-
omy process, to this end each phlebotomy staff member 
has a “P Number”, which is recorded with each sample 
collected. If preanalytical issues are identified, the staff 
member responsible can be contacted, corrective action 
taken and focused education and training provided when 
needed.
The phlebotomy service has worked since 2012 to 
review and implement blood collection devices that 
ensures sample quality and enhances patient care. Two 
safety devices with integrated “flash” to indicate the 
correct insertion into the vein, the BD Eclipse™ Signal™ 
blood collection needle (Becton Dickinson) and BD Vacu-
tainer® The Push Button Blood Collection set (Becton 
Dickinson) was trialed and implemented, with training to 
ensure that the correct device was used for venous access 
in different scenarios.
Both devices increased healthcare worker safety with 
71% reduction in needlestick injuries recorded for blood 
collection set [27]. Phlebotomy staff liked the ergonomic 
design and the safety improvements in both products, and 
felt that the product design matched the needs of phlebot-
omy team. There have updates to the devices such as the 
BD UltraTouch™ technology on the blood collection set 
which have increased the internal diameter of the needle 
lumen, whilst maintaining the same external diameter 
[28]. These changes increased the flow rate of blood into 
the sample tubes, and decreased the penetration force, 
which have resulted in positive patient feedback during 
their use.
Managing laboratory demand 
 strategies: some actual examples  
of their usefulness
Clinical laboratory plays a dominant role in the overall 
health care process, as diagnostic information is involved 
in as many as 70% of clinical decisions. The multi-step 
laboratory process begins when the clinicians choose the 
tests and ends when interpreting laboratory reports. Evi-
dence was found that under-requesting diagnostic tests 
may result in failed disease prevention, missed diagnosis 
and improper disorder monitoring. On the other hand, 
over-requesting tests generates high costs and may lead to 
further unnecessary testing and significant adverse effects 
[29]. The clinical laboratory is susceptible to turning into 
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a solely data-vending industry, and the clinical laboratory 
professional is at risk of not considering knowledge deliv-
ery instead of data. The results of some tests may not be 
useful in certain diagnoses but could hide valuable infor-
mation. Overall, inappropriately requesting laboratory 
tests not only jeopardizes the clinical decision making 
and patient safety, but also dissipates valuable health 
system resources.
The Appropriate Utilization of Laboratory Tests Group 
(REDCONLAB) was created to build a network of shared 
knowledge among Spanish clinical laboratories, with the 
aim of providing health services of the highest quality in 
the context of management excellence. Through the study 
of regional differences with the use of key performance 
indicators (KPIs), a globally high variability inappro-
priateness of test requests could be detected. A series of 
automatic strategies were designed and according to sci-
entific evidence, in consensus with clinicians and based 
on laboratory information systems (LISs) and patient data 
bases (PDBs). Specific interventions aimed to decrease the 
number of uric acid and transferrin tests were designed and 
implemented in primary care settings, which generated a 
significant decrease of allopurinol prescription by general 
practitioners and were also associated with considerable 
savings. To deal with the low number of requests of both 
calcium and HbA1c, additional strategies were designed for 
detecting asymptomatic hyperparathyroidism and occult 
diabetes, yielding to a mean cost per patient lower than 
€100, so increasing laboratory visibility and maximizing 
the benefits for patients and society [30–32].
Targeted thyroid testing in acute 
illness – achieving success through 
audit and teaching
Thyroid test results in acutely ill patients are often abnor-
mal, discordant and confusing. They are also mostly 
ignored by physicians who order them, and not repeated 
or followed up. Hence, it is plausible that they may not 
enhance patient outcomes. Despite the above, there is evi-
dence that thyroid testing is on the increase, in an effort to 
diagnose subtle thyroid abnormalities which benefit from 
intervention, and because symptoms of thyroid disease 
are very non-specific. These thyroid abnormalities, part 
of what is now called the non-thyroidal illness syndrome 
(NTIS), are known to affect up to 40%–70% of acutely 
ill patients, and are known to occur in non-critically ill 
patients as well. The mechanisms of NTIS are multiple 
and complicated, and are now becoming clearer. Hitherto, 
there has been no convincing evidence of a benefit to 
intervention with thyroid hormone. The difficulty in 
interpreting discordant thyroid results, the lack of clarity 
about the benefits of intervention, and potential cost 
savings, favor a restricted thyroid testing policy. Amongst 
the methods of reducing thyroid test requests in these cir-
cumstances, altering requestor behavior is an attractive 
option. In this regard, audits of local practice, the issue 
of guidelines (reducing thyroid tests from 53.8% to 21.7% 
in acutely ill subjects; p = 0.01), and education of health-
care professionals (reducing thyroid tests requested per 
patient from 0.32 before intervention vs. 0.08 post inter-
vention; p < 0.001) have been successful, and have signifi-
cantly reduced thyroid testing where they have been tried 
[33, 34]. We currently recommend that thyroid tests should 
be restricted during acute admissions to only those with 
(a) known thyroid disease, (b) clinical features and risk 
factors for thyroid disease, (c) the use of drugs potentially 
affecting thyroid function, and (d) the presence of unex-
plained tachydysrhythmias.
Diagnostic pathways – when? how? 
benefits
Effective test ordering, based on guidelines rather than 
“gut feelings”, is a serious issue in the pre-analytical 
phase – especially in the context of diagnosis related 
group (DRG)-based reimbursement in hospitals. In 2006, 
the German Association for Clinical Chemistry and Labo-
ratory Medicine started an initiative aiming to define spe-
cific rules for implementation of standardized diagnostic 
pathways [35]. In 2011, the task force published a widely 
recognized handbook, which is also available in English 
[36]. Meanwhile, the task force represents four German-
speaking countries (Germany, Austria, Switzerland and 
Liechtenstein).
Diagnostic pathways are an essential subset of clini-
cal pathways, combining the principle of stepwise reflex 
testing with a management concept that helps to fulfill 
medical needs with economic efficacy. The computational 
basis “if…then…else” rules can easily be visualized as 
decision trees. From a laboratory perspective, diagnostic 
pathways represent “smart” test profiles, which – in con-
trast to inflexible profiles – are not necessarily worked off 
completely, but just to the point where a diagnostic deci-
sion can be made. The handbook includes over 80 such 
decision trees, which have been worked out jointly by lab-
oratory and clinical experts and are based on published 
guidelines, whenever possible. The standardized format 
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facilitates the implementation of the underlying rules in 
electronic order entry and laboratory information systems.
The benefits of the diagnostic pathway concept 
are many. Decision trees make the optimal diagnostic 
pathway transparent, thus improving the mutual under-
standing between laboratory and clinicians. Automatic 
ordering of smart profiles saves time, avoids errors at 
clinical sites and provides the laboratory with a tentative 
diagnosis or clinical question. Guideline-based ordering 
improves outcomes and saves money by making sure that 
no essential tests are missed, while unnecessary requests 
are avoided. Stepwise testing reduces the number of false 
positive results, especially when decision limits are based 
on contemporary statistical algorithms.
Drivers for and examples of demand 
management in the UK
Most hospitals in the UK National Healthcare System 
(NHS) operate with a financial deficit, so leading to pres-
sure from various sources for saving money. Laboratories 
are being driven to do this by commissioners, clinicians, 
professional bodies as well as from within the laboratory. 
One strategy for laboratories to save money is reducing 
the number of tests performed, the other entails reduc-
ing the staff. This can be done by reducing the number 
of inappropriate laboratory investigations, i.e. by manag-
ing demand. Nevertheless, the profession must remain 
patient-centered and demand management should not be 
about just ensuring that unnecessary tests are requested, 
but also ensuring that the physicians get the right tests, at 
the right time, done in the right way and in a reasonable 
time. Demand management will thus increase some test 
numbers and decrease others, so that the better strategy 
may be tailored to target appropriate test requesting and 
not managing demand.
Fryer et al. [37] suggested a list of 27 recommendations 
for demand management. The first few of these focus upon 
establishing benchmarks. There have been a number 
of UK initiatives to perform this function, including the 
NHS Atlas of Variation and Keele University Bechmark-
ing Project. This resource highlighted the huge variation 
existing in requesting practices between different users, 
which appeared mostly attributable to clinical practice 
and not variation in patient populations [38]. There are 
various tools that can be used to ensure appropriateness 
of testing, and all these require collaboration between the 
laboratory and its users. Establishing agreed clinical con-
dition specific profiles is one mechanism to ensure that 
the right tests are performed to properly investigate the 
clinical query. By adding automated cascade testing to 
this, laboratories can ensure that only the right tests are 
performed. Minimum retest intervals can also be used to 
ensure that tests are only repeated after a clinically rel-
evant timeframe and not before [39]. Finally, education is 
also a key determinant to ensuring that only appropriate 
testing is performed [40].
“Choosing Wisely”: a US  initiative 
to reduce wasteful practices 
in medicine
The American Board of Internal Medicine Foundation, 
in concert with nine other US medical specialty boards, 
introduced the “Choosing Wisely” campaign in April of 
2012 to improve medical decision making by physicians 
and patients [41]. As the choice to order a laboratory test 
is the first step in the so-called “brain to brain” loop, this 
initiative can be viewed as a national effort to improve the 
very earliest part of the preanalytical phase. Over the past 
5 years, the initiative has grown with hundreds of recom-
mendations from over 70 medical societies, accessible on 
a website [42], which also hosts patient-directed recom-
mendations in partnership with the US non-profit organi-
zation Consumer Reports. Unlike guidance from other 
medical organizations, the items in Choosing Wisely lists 
are usually directives aimed not to avoid doing some-
thing, rather than recommendations to take any specific 
action. Recommendations dealing with laboratory testing 
include the Society for Hospital Medicine and the Critical 
Care Societies Collaborative both individually discourag-
ing daily laboratory testing on inpatients, the American 
Academy of Allergy, Asthma and Immunology exhorta-
tion to avoid indiscriminate immunoglobulin E (IgE) 
batteries evaluating allergy, and the American Society 
for Clinical Pathology recommendations to use troponin 
instead of creatine kinase MB (CK-MB) and not ordering 
expanded lipid panels, among other recommendations. 
The Choosing Wisely initiative has now moved towards 
focusing on interventions that implement the recom-
mendations, with numerous success stories (Choosing 
Wisely “Champions”) linked on their website. While the 
initiative has not gone without criticism, i.e. not all rec-
ommendations have been developed with standardized 
methodology or undisputed evidence [43], and other rec-
ommendations are perceived as difficult to implement 
[44], the initiative still represents an important attempt to 
reduce overutilization of medical interventions, including 
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laboratory testing, that are not expected to be beneficial 
for the patients.
Challenges of point-of-care testing 
in the intensive care unit
Critically ill patients in intensive care units (ICUs) are 
treated for life-threatening disease and intensivists must 
deal with sudden evolution of the clinical course, so 
undertaking prompt and appropriate clinical decisions. 
Rapid biological assessment is a keystone for decision-
making process. Thus, the long TAT from blood sam-
pling withdrawal to the test result (mainly attributable to 
issues related to sample shipping) must be shortened to 
deal with emergency situations. The use of point-of-care 
testing (POCT) offers a real advantage in the management 
of ICU patients. It substantially reduces the TAT for deliv-
ering results and provides immediate answers to physi-
cian interrogations. It was actually demonstrated that a 
blood gas analyzer located in an ICU strongly contributes 
to rapid medical decision-making process, including ven-
tilator setting adjustment along with red blood cell trans-
fusions or emergency treatment of dyskalemia [45]. The 
“therapeutic” TAT (i.e. the time between ordering a test 
and interpretation of its results to undertake a final deci-
sion) was reduced to 15 min with the POCT, compared to 
2 h with the central laboratory [45]. Therefore, an increas-
ing number of ICUs have included POCT devices in their 
technical facilities. Many tests such as bicarbonate, pH, 
partial pressure of carbon dioxide (pCO2), partial pressure 
of oxygen (pO2), sodium, potassium, ionized calcium, 
hematocrit, glucose, lactate, creatinine, chlorine are cur-
rently measured at bedside. Markers of organ failure such 
as cardiac troponin, brain natriuretic peptide, neutrophil 
gelatinase-associated lipocalin (NGAL) are also increas-
ingly used. ICUs have access to advanced equipment and 
will probably absorb further innovating POCT technolo-
gies in the future. For instance, smartphone-based diag-
nostic approaches will probably usher in a new chapter in 
POCT. Although these technological innovations are highly 
exciting for physicians, POCT analyses are performed by 
non-laboratory staff, in diverse clinical contexts in which 
the POCT users have varying levels of experience with the 
device. The preanalytical phase, performed outside the 
direct supervision of laboratory professionals, could be 
an important reason for variability of POCT performance. 
Studies on reliability of POCT in ICU have provided con-
troversial results, but these investigations were mainly 
focused on the analyzer rather than on the preanalytical 
phase. When integrating the global process of POCT, from 
the bedside to final result, it was clearly demonstrated 
that an identical analyzer could provide various quality of 
results according to the local constraint of the ICUs [46]. 
Although internal quality programs are implemented by 
POCT suppliers, these systems cannot overcome all the 
issues generated during the preanalytical phase. Interest-
ingly, the underperformance of POCT can be significantly 
improved, so providing reliable results by a tight collabo-
ration between users (ICU staff) and providers (laboratory 
staff). It is now possible to bring laboratory tests closer to 
the patient, but it is imperative to monitor their reliability 
in the exact condition of use.
POCT innovations from a labatory 
point of view
The implementation of POCT in an emergency department 
(ED) setting has been suggested as a means to increase 
timely discharge rates, shorten length of stay and increase 
patient throughput.
An increase in waiting and processing time, a lack 
of beds, capacity in the ED, a general perception of being 
rushed by emergency physicians and staff, increased 
ambulance diversions and increased frequency of patients 
leaving the ED without being seen, are all signals that the 
ED is overcrowding.
The use of history electrocardiogram age risk factors 
troponin (Heart) score may help mitigating this over-
crowding situation by reducing the number of patients 
in the ED. The triage of patients with chest pain usually 
occurs in the hospital emergency room. It has been shown 
that the HEART score offers a simple and quick risk-strat-
ification tool for these patients. Results of the FamouS 
Triage demonstrate the feasibility of a pre-hospital chest 
pain triage in the ambulance by paramedics [47].
Innovations regarding glucose measurements are 
focused on stabilizing glucose in tubes, interstitial con-
tinuous glucose measurement (CGM), intravenous CGM 
and non-invasive glucose measurements. CGM may suffer 
from a lack of time in respect to venous blood glucose 
levels. CGM can provide additional information regarding 
both direction and rapidity of change of glucose values. 
As such, it can be of additional value to patients for pre-
venting derangements of glucose values. Non-invasive 
glucose measurements are in development, and may also 
suffer from this lack of time. Sophisticated software can 
be helpful for timely warning of patients. A good labora-
tory verification protocol for CGM is currently lacking. Its 
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development may thus help to test combinations of condi-
tions that only occasionally will be observed in patients 
and may therefore not be present during patient evalua-
tion studies. POCT is also applied for home-care of heart-
failure patients and may help to improve medication 
adjustments.
Innovation in the preanalytical 
phase of POCT testing
POCT, most frequently performed in the ED, ICUs and 
operation rooms, provides rapid diagnostic information 
about patient status, enabling faster clinical decision-
making, intervention and increased patient throughput, 
but is also increasingly used in extra-hospital settings 
such as pharmacies and markets, for auto-screening and 
auto-diagnosis [48]. The POC tests are typically performed 
with venous, arterial or capillary whole blood samples, 
depending on the specified analyte and required patient 
care. While POCT offers quicker test turnaround and ease 
of use, the benefits may be offset by less analytical sen-
sitivity/precision and higher risk of interferences [49]. 
Although analytical issues are very frequent, preanalyti-
cal errors account for up to 32% of POC errors. This may 
be underestimated, as preanalytical errors may go unde-
tected due to lack of user knowledge and limited systems 
for identifying errors [50].
Innovation by medical companies is more than just 
good product design. It starts by understanding user 
needs and expectations. To understand these needs, 
interviews are conducted, questionnaires implemented 
and customer processes observed. Recent research has 
highlighted important issues about the current acute care 
POC tests, as conveyed by clinicians. Minimizing errors 
due to preanalytical variables has been identified as an 
important unmet need. Other issues included poor sample 
quality (hemolysis, micro-clots, air bubbles), sample han-
dling challenges, inefficient workflow due to complex 
sample collection, and risk of healthcare worker exposure 
to bloodborne pathogens. Unlike core labatory processes, 
sample collection and management are not standard, with 
facilities implementing unique solutions. These processes 
can lead to safety concerns from unnecessary needle and 
blood exposure. Currently, frequent training, monitor-
ing and competency assessment of the diverse users who 
collect POC samples (nurses, phlebotomists, respiratory 
therapists and other health professionals) are the only 
risk mitigation tools available to manage POC preanalyti-
cal variability.
Once understood, key unmet customer needs are uti-
lized to design and develop devices that address this envi-
sioned future in POCT, so helping to improve healthcare 
worker and patient safety and optimizing outcomes for 
patients and hospital.
Pre-analytical EQAS program 
for POCT users
A substantial difference exists between pre-analytical 
external quality assessment scheme (EQAS) program 
for POCT and for central laboratory users [51]. Concern-
ing POCT users, the EQA organizers are communicating 
directly with the users of tests and their co-workers. It 
is therefore important that this category of health per-
sonal find the EQA program useful and to the benefit of 
their patients [52]. The Norwegian Quality Improvement 
of Laboratory Examinations (Noklus), for example, offers 
different kinds of pre-analytical programs for POCT users: 
(1) Pre-pre examinations program about what to test to 
request and what to analyze in specific clinical situations. 
This is often performed through case histories, circulated 
to general practitioners (GPs) and clinicians in nursing 
homes. Such programs are often combined with a post-
examination program about test interpretation. Typical 
examples are case histories about the use of urine strips, 
C-reactive protein (CRP) and the international normal-
ized ratio (INR). (2) Pre-examination surveys concerning 
what procedures GP-offices or nursing homes have for 
exampling concerning handling of capillary and venous 
samples and patient identifications. Feedback is given 
and consists of guidelines and recommendations for spe-
cific topics. E-learning programs are developed both for 
clinicians and co-workers.
EFLM WG-PRE project: European 
recommendation for venous blood 
sampling
Venous blood sampling is the most common invasive 
procedure in health care, available worldwide. Further-
more, venous blood sampling is the most common source 
of preanalytical variability, which may not only jeopard-
ize sample quality but also put patient safety at risk. 
Although commonly considered as a simple procedure, 
the truth is that skilled and educated personnel with a 
good understanding of the procedure and associated 
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risks are of the utmost importance in order to minimizing 
the risk for compromising the quality of the sample and 
ensuring patient safety during the venous blood sampling 
procedure [53]. Unfortunately, many European countries 
do not have their own national guidelines for venous 
blood sampling. Moreover, there is a large heterogeneity 
of the staff which currently performs venous blood sam-
pling in Europe in terms of their background education, 
life-long learning opportunities, medical education, com-
petence and skills [54]. Education about preanalytical 
phase is not available even at a large proportion of uni-
versity level curricula in biomedicine and original studies 
have demonstrated that students in biomedicine are not 
well educated about the various sources of preanalytical 
variability [55]. Obviously, there is a room for improve-
ment and harmonization of this important preanalytical 
step is necessary. The EFLM WG-PRE has this issue high 
on its agenda and has therefore recently initiated a project 
with the aim to develop joint consensus recommenda-
tion for venous blood sampling practices in Europe. This 
document has been developed in close collaboration of 
representatives from over 1/3 of all EFLM national socie-
ties as well as with representatives from the association of 
nurses, phlebotomists and IVD partners and is now in its 
final stage. Focus and guidance on the implementation of 
the guidelines is what makes the added value of this docu-
ment in comparison with already existing guidelines and 
recommendations. Moreover, the EFLM recommendation 
is accompanied by some useful tools which are developed 
by the EFLM WG-PRE and will be made freely available for 
all EFLM national societies and other interested parties 
from the EFLM website. The EFLM WG-PRE is hoping 
that this document will be endorsed by all EFLM national 
societies. Only through such universal acceptance and 
implementation, can true harmonization of venous blood 
sampling and patient safety improvement across Europe 
be achieved.
Obviously, improving preanalytical quality is a 
challenging enterprise, requiring major effort through-
out the various phases of this process and implementa-
tion of various interventions, such as education, regular 
monitoring and audits. Among the various interventions, 
broadening EQA schemes to blood collection and other 
extra-analytical activities should be regarded as a valu-
able perspective. Such initiatives are not only educational 
but can also aid in identifying critical steps and room for 
improvement. One such initiative was recently described 
in a study summarizing results from six rounds of preana-
lytical EQA during 2014–2016 in 175 Croatian laboratories, 
which showed that major critical spots during phlebot-
omy in Croatia were the lack of availability of safe-sharp 
needles, disposable tourniquets and glucose inhibitor 
tubes. The data may obviously differ from country to 
country, pointing to the need for more engagement of 
national professional associations in this area to assess 
the local specificities and requirements [56].
Presentation of the Austrian pilot 
study on venous blood sampling
The WG-PRE is currently working to drafting a consen-
sus guideline for venous blood collection and sample 
handling, including an adaptable PowerPoint (PPT) pres-
entation, reflecting the contents of the guideline, a test 
to examine the knowledge after training as well as an 
observational checklist to be able to see if the trainees are 
using their newly gained knowledge correctly in practice. 
Whereas the observational checklist has already been suc-
cessfully piloted in one laboratory in Odense (Denmark) 
[57], here we wish to present the results of the pilot project 
on venous blood sampling in one Austrian hospital.
A pilot study was recently undertaken involving the 
pediatric wards of the University Hospital of Salzburg 
(Austria) to evaluate practicability in a real life health care 
setting, where phlebotomy tasks were shifted from physi-
cians to the nursing staff. The PPT presentation including 
the mentioned knowledge test which was transformed 
into an e-learning module with a single-user login. All 240 
pediatric nurses were advised to complete this module 
and at least 70% of questions had to be answered cor-
rectly in the mandatory knowledge test. Practical training 
using demo arms was also carried out under the supervi-
sion of experienced nurses. Practical skills were randomly 
monitored by using the mentioned observational sheets to 
evaluate their practical usefulness. In a study performed 
on other wards of the same hospital, preanalytical edu-
cation was found to be effective for improving sample 
quality even if the phlebotomy task was shifted from few 
experienced health care workers to inexperienced staff 
[58]. To gain phlebotomy skills, and subsequently improv-
ing sample quality, experience time is needed. Unfortu-
nately, it seems too early to evaluate respective data from 
our pediatric wards at this point in time. As our pilot study 
was aimed to evaluate the upcoming consensus guide-
lines and the accompanied documents, we can however 
conclude that these may be regarded as valuable tools, 
which were very well accepted by our nursing staff. They 
are adaptable to fit local health care settings and regula-
tions and very easy to implement. Given the precondition 
of the hospital management backing such an educational 
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project, we found the guidelines and the tools a very prac-
tical solution to implement standardized venous blood 
collection and sample handling even in large collectives.
Managing the quality of blood 
sampling through education
Improved knowledge and awareness of clinical guidelines 
reduces mistakes in health care. The application of clini-
cal guidelines, as well as the way they are implemented, 
are impacted by several issues [59]. An intensive effort to 
implement and sustain adherence to venous blood sam-
pling guidelines among phlebotomists has been carried 
out between 2009 and 2016 in Västerbotten County 
Council, Sweden. In 2009, staff attended a compulsory 
education comprising of 2-h oral lecture and a knowl-
edge test on venous blood sampling guidelines practices. 
Evaluation of education demonstrated improvements in 
self-reported practices, such as patient identification and 
test tube labeling, but blood sample quality monitored as 
sample hemolysis only showed minor differences.
Web-based programs can be appropriate for large 
organizations, are cheap and give flexible opportunities 
as they are accessible for phlebotomists in rural areas 
[60]. Therefore, in 2013 we replaced the traditional educa-
tion with a web-based program developed in cooperation 
with media educators, phlebotomists and university lec-
turers. The final web-based program includes appropriate 
monitoring and feedback mechanisms, contains instruc-
tive movies, interactive assignments along with clickable 
explanatory text. It also highlights high risk steps such 
as patient identification and test tube labeling to ensure 
patient safety [61].
We then investigated whether the web-based program 
was effective to improve venous blood specimen collec-
tion practices compared to the traditional educational 
program. Phlebotomists (n = 460 in 2007; n = 995 in 2013; 
n = 459 in 2016) self-reported adherence to venous sam-
pling guidelines was collected through a validated ques-
tionnaire. We also collected user experiences regarding 
e-learning to assess its usefulness and to perform neces-
sary corrective measures. The questionnaires was ana-
lyzed using statistics and content analysis. Preliminary 
results show that the adherence to venous blood sampling 
guideline practices was improved with respect to identifi-
cation procedures and test tube labeling, and that phle-
botomists perceived that the web-based program allowed 
direct feed-back, motivated reflection and was easy to 
navigate.
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